에드하임 체스터병(ECD) : 시장 인사이트, 역학 및 시장 예측(2034년)

Erdheim-Chester Disease (ECD) - Market Insight, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,017,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 16,525,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 22,034,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 33,051,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이 보고서는 미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본 등 7개 주요 에드하임 체스터병(ECD) 시장을 조사 분석하여 각 지역 시장 규모, 현재 치료법, 미충족 수요, 새로운 치료법 등에 대한 정보를 제공합니다.

목차

제1장 프리미엄 인사이트

제2장 에드하임 체스터병(ECD) 주요 요약

제3장 에드하임 체스터병(ECD) 경쟁 정보 분석

제4장 에드하임 체스터병(ECD) : 시장 개요

• 에드하임 체스터병(ECD) 전체 시장 점유율 분포(2020년)
• 에드하임 체스터병(ECD) 전체 시장 점유율 분포(2034년)

제5장 에드하임 체스터병(ECD) : 질환의 배경과 개요

• 서론
• 징후와 증상
• 병태생리학
• 위험 요인
• 진단

제6장 환자 여정

제7장 에드하임 체스터병(ECD) 역학과 환자 인구

• 역학 주요 조사 결과
• 전제조건과 근거 : 주요 7개 시장
• 역학 시나리오 : 주요 7개 시장
  • 주요 7개 에드하임 체스터병(ECD) 역학 시나리오(2020년-2034년)
• 미국의 역학
  • 미국의 에드하임 체스터병(ECD) 역학 시나리오(2020년-2034년)
• 유럽 5개국 역학 : 국가별
  • 독일의 역학
  • 프랑스 역학
  • 이탈리아 역학
  • 스페인 역학
  • 영국의 역학
  • 일본 역학

제8장 치료 알고리즘, 현재의 치료 및 의료 행위

• 에드하임 체스터병(ECD) 치료와 관리
• 에드하임 체스터병(ECD) 치료 알고리즘

제9장 미충족 요구

제10장 에드하임 체스터병(ECD) 치료의 주요 평가항목

제11장 출시 제품

제12장 새로운 치료법

제13장 에드하임 체스터병(ECD) : 주요 7개 시장 분석

• 주요 조사 결과
• 주요 7개 에드하임 체스터병(ECD) 시장 규모
• 주요 7개 에드하임 체스터병(ECD) 시장 규모 : 치료법별

제14장 속성 분석

제15장 주요 7개 시장 : 시장 전망

• 미국 : 시장 규모
  • 미국의 에드하임 체스터병(ECD) 전체 시장 규모
  • 미국의 에드하임 체스터병(ECD) 시장 규모 : 치료법별
• 유럽 5개국 : 시장 규모와 전망
• 독일 : 시장 규모
  • 독일의 에드하임 체스터병(ECD) 전체 시장 규모
  • 독일의 에드하임 체스터병(ECD) 시장 규모 : 치료법별
• 프랑스 시장 규모
• 이탈리아 시장 규모
• 스페인 시장 규모
• 영국 : 시장 규모
  • 영국의 에드하임 체스터병(ECD) 전체 시장 규모
  • 영국의 에드하임 체스터병(ECD) 시장 규모 : 치료법별
• 일본 시장 전망
  • 일본 시장 규모

제16장 에드하임 체스터병(ECD) 접근 및 상환 개요

제17장 KOL(Key Opinion Leader)의 견해

제18장 시장 성장 촉진요인

제19장 시장 장벽

제20장 부록

제21장 DelveInsight의 서비스 내용

제22장 면책사항

제23장 DelveInsight에 대해

LSH

영문 목차

영문목차

DelveInsight's "Erdheim-Chester Disease (ECD) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Erdheim-Chester Disease (ECD), historical and forecasted epidemiology as well as the Erdheim-Chester Disease (ECD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Erdheim-Chester Disease (ECD) market report provides current treatment practices, emerging drugs, Erdheim-Chester Disease (ECD) market share of the individual therapies, current and forecasted Erdheim-Chester Disease (ECD) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Erdheim-Chester Disease (ECD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Erdheim-Chester Disease (ECD) Disease Understanding and Treatment Algorithm

The DelveInsight Erdheim-Chester Disease (ECD) market report gives a thorough understanding of the Erdheim-Chester Disease (ECD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Erdheim-Chester Disease (ECD).

Treatment

It covers the details of conventional and current medical therapies available in the Erdheim-Chester Disease (ECD) market for the treatment of the condition. It also provides Erdheim-Chester Disease (ECD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Erdheim-Chester Disease (ECD) Epidemiology

The Erdheim-Chester Disease (ECD) epidemiology division provide insights about historical and current Erdheim-Chester Disease (ECD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Erdheim-Chester Disease (ECD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Erdheim-Chester Disease (ECD) Epidemiology

The epidemiology segment also provides the Erdheim-Chester Disease (ECD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Erdheim-Chester Disease (ECD) Drug Chapters

Drug chapter segment of the Erdheim-Chester Disease (ECD) report encloses the detailed analysis of Erdheim-Chester Disease (ECD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Erdheim-Chester Disease (ECD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Erdheim-Chester Disease (ECD) treatment.

Erdheim-Chester Disease (ECD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Erdheim-Chester Disease (ECD) treatment.

Erdheim-Chester Disease (ECD) Market Outlook

The Erdheim-Chester Disease (ECD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Erdheim-Chester Disease (ECD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Erdheim-Chester Disease (ECD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Erdheim-Chester Disease (ECD) market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Erdheim-Chester Disease (ECD) market in 7MM.

The United States Market Outlook

This section provides the total Erdheim-Chester Disease (ECD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Erdheim-Chester Disease (ECD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Erdheim-Chester Disease (ECD) market size and market size by therapies in Japan is also mentioned.

Erdheim-Chester Disease (ECD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Erdheim-Chester Disease (ECD) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Erdheim-Chester Disease (ECD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Erdheim-Chester Disease (ECD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Erdheim-Chester Disease (ECD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Erdheim-Chester Disease (ECD) emerging therapies.

Reimbursement Scenario in Erdheim-Chester Disease (ECD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Erdheim-Chester Disease (ECD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Erdheim-Chester Disease (ECD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Erdheim-Chester Disease (ECD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Erdheim-Chester Disease (ECD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Erdheim-Chester Disease (ECD) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Erdheim-Chester Disease (ECD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Erdheim-Chester Disease (ECD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Erdheim-Chester Disease (ECD) market

Report Highlights:

• In the coming years, Erdheim-Chester Disease (ECD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Erdheim-Chester Disease (ECD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Erdheim-Chester Disease (ECD). Launch of emerging therapies will significantly impact the Erdheim-Chester Disease (ECD) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Erdheim-Chester Disease (ECD)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Erdheim-Chester Disease (ECD) Report Insights

• Patient Population
• Therapeutic Approaches
• Erdheim-Chester Disease (ECD) Pipeline Analysis
• Erdheim-Chester Disease (ECD) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Erdheim-Chester Disease (ECD) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Erdheim-Chester Disease (ECD) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Erdheim-Chester Disease (ECD) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Erdheim-Chester Disease (ECD) market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Erdheim-Chester Disease (ECD) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Erdheim-Chester Disease (ECD) market size during the forecast period (2024-2034)?
• At what CAGR, the Erdheim-Chester Disease (ECD) market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Erdheim-Chester Disease (ECD) market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Erdheim-Chester Disease (ECD) market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Erdheim-Chester Disease (ECD)?
• What is the historical Erdheim-Chester Disease (ECD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Erdheim-Chester Disease (ECD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Erdheim-Chester Disease (ECD)?
• Out of all 7MM countries, which country would have the highest prevalent population of Erdheim-Chester Disease (ECD) during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Erdheim-Chester Disease (ECD) treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Erdheim-Chester Disease (ECD) in the USA, Europe, and Japan?
• What are the Erdheim-Chester Disease (ECD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Erdheim-Chester Disease (ECD)?
• How many therapies are developed by each company for Erdheim-Chester Disease (ECD) treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Erdheim-Chester Disease (ECD) treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Erdheim-Chester Disease (ECD) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Erdheim-Chester Disease (ECD) and their status?
• What are the key designations that have been granted for the emerging therapies for Erdheim-Chester Disease (ECD)?
• What are the global historical and forecasted market of Erdheim-Chester Disease (ECD)?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Erdheim-Chester Disease (ECD) market
• To understand the future market competition in the Erdheim-Chester Disease (ECD) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Erdheim-Chester Disease (ECD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Erdheim-Chester Disease (ECD) market
• To understand the future market competition in the Erdheim-Chester Disease (ECD) market

Table of Contents

1. Key Insights

2. Executive Summary of Erdheim-Chester Disease (ECD)

3. Competitive Intelligence Analysis for Erdheim-Chester Disease (ECD)

4. Erdheim-Chester Disease (ECD): Market Overview at a Glance

• 4.1. Erdheim-Chester Disease (ECD) Total Market Share (%) Distribution in 2020
• 4.2. Erdheim-Chester Disease (ECD) Total Market Share (%) Distribution in 2034

5. Erdheim-Chester Disease (ECD): Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Erdheim-Chester Disease (ECD) Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Erdheim-Chester Disease (ECD) Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Erdheim-Chester Disease (ECD) Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Erdheim-Chester Disease (ECD) Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Erdheim-Chester Disease (ECD) Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Erdheim-Chester Disease (ECD) Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Erdheim-Chester Disease (ECD) Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Erdheim-Chester Disease (ECD) Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Erdheim-Chester Disease (ECD) Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Erdheim-Chester Disease (ECD) Treatment and Management
• 8.2. Erdheim-Chester Disease (ECD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Erdheim-Chester Disease (ECD) Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Erdheim-Chester Disease (ECD): Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Erdheim-Chester Disease (ECD) Market Size in 7MM
• 13.3. Erdheim-Chester Disease (ECD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Erdheim-Chester Disease (ECD) Total Market Size in the United States
  • 15.1.2. Erdheim-Chester Disease (ECD) Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Erdheim-Chester Disease (ECD) Total Market Size in Germany
  • 15.3.2. Erdheim-Chester Disease (ECD) Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Erdheim-Chester Disease (ECD) Total Market Size in France
  • 15.4.2. Erdheim-Chester Disease (ECD) Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Erdheim-Chester Disease (ECD) Total Market Size in Italy
  • 15.5.2. Erdheim-Chester Disease (ECD) Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Erdheim-Chester Disease (ECD) Total Market Size in Spain
  • 15.6.2. Erdheim-Chester Disease (ECD) Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Erdheim-Chester Disease (ECD) Total Market Size in the United Kingdom
  • 15.7.2. Erdheim-Chester Disease (ECD) Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Erdheim-Chester Disease (ECD) Total Market Size in Japan
  • 15.8.3. Erdheim-Chester Disease (ECD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Erdheim-Chester Disease (ECD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

관련자료